SNCE Stock Overview
Science 37 Holdings, Inc. provides technology-based solutions to enable agile clinical trials and decentralized approaches.
Science 37 Holdings, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.59|
|52 Week High||US$14.44|
|52 Week Low||US$0.54|
|1 Month Change||-59.59%|
|3 Month Change||-59.59%|
|1 Year Change||-93.99%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-94.13%|
Recent News & Updates
|SNCE||US Life Sciences||US Market|
Return vs Industry: SNCE underperformed the US Life Sciences industry which returned -26.1% over the past year.
Return vs Market: SNCE underperformed the US Market which returned -14.8% over the past year.
|SNCE Average Weekly Movement||15.4%|
|Life Sciences Industry Average Movement||11.2%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: SNCE is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: SNCE's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Science 37 Holdings, Inc. provides technology-based solutions to enable agile clinical trials and decentralized approaches. Its platform enables modern and digital approaches to clinical research by bringing together all parties, including the patient and trial investigators, nurses, coordinators, and sponsors to power workflows, centralize evidence generation, and harmonize data. Its platform also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices for orchestrating agile clinical trials; and extensive configuration to support virtually any phase of clinical study and any indication.
Science 37 Holdings, Inc. Fundamentals Summary
|SNCE fundamental statistics|
Is SNCE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SNCE income statement (TTM)|
|Cost of Revenue||US$54.73m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.42|
|Net Profit Margin||-66.45%|
How did SNCE perform over the long term?See historical performance and comparison